NUVL (Nuvalent) Float Percentage Of Total Shares Outstanding : 38.02% (As of May. 03, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Nuvalent Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Nuvalent's float shares is 27.30 Mil. Nuvalent's total shares outstanding is 71.80 Mil. Nuvalent's float percentage of total shares outstanding is 38.02%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Nuvalent's Insider Ownership is 2.77%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Nuvalent's Institutional Ownership is 98.60%.

Nuvalent Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Nuvalent's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	27.30	/	71.80
	=	38.02%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nuvalent Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvalent Inc (NAS:NUVL) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Broadway, 14th Floor, Cambridge, MA, USA, 02142

Website

https://www.nuvalent.com

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Executives

James Richard Porter	director, officer: President and CEO	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Darlene Noci	officer: See Remarks	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Matthew Shair	director	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Deborah Ann Miller	officer: Chief Legal Officer	C/O NUVALENT, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Alexandra Balcom	officer: Chief Financial Officer	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Christopher Durant Turner	officer: Chief Medical Officer	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Hack Andrew A. F.	director	300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
James E Flynn	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Emily Conley	director	C/O NUVALENT, INC., ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA 02142
Anna Protopapas	director	MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Deerfield Mgmt L.p.	director, 10 percent owner, other: * Director by deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p.	director, 10 percent owner, other: Director by Deputization	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Michael L. Meyers	director	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Deerfield Private Design Fund Iv, L.p.	director, 10 percent owner, other: Director by Deputization	780 THIRD AVENUE 37TH FLOOR, NEW YORK NY 10017
Robert Bowers Jackson	director	C/O NUVALENT, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142